(Q33861117)

29 July 2017

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial (English)

1 reference

29 July 2017

0 references

0 references

Michael W Konstan

1

1 reference

29 July 2017

Patrick A Flume

2

1 reference

29 July 2017

Matthias Kappler

3

1 reference

29 July 2017

Raphaël Chiron

4

1 reference

29 July 2017

Mark Higgins

5

1 reference

29 July 2017

Florian Brockhaus

6

1 reference

29 July 2017

Jie Zhang

7

1 reference

29 July 2017

Gerhild Angyalosi

8

1 reference

29 July 2017

Ellie He

9

1 reference

29 July 2017

David E Geller

10

1 reference

29 July 2017

12 November 2010

1 reference

Journal of Cystic Fibrosis

29 July 2017

1 reference

29 July 2017

10

1 reference

29 July 2017

1

1 reference

29 July 2017

54-61

1 reference

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Bugs, biofilms, and resistance in cystic fibrosis.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

High treatment burden in adults with cystic fibrosis: challenges to disease self-management

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Changes in the normal maximal expiratory flow-volume curve with growth and aging

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086197

Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21075062

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21075062

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Understanding non-compliance with treatment in adults with cystic fibrosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21075062

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.JCF.2010.10.003

1 reference

29 July 2017

1 reference

29 July 2017

1 reference